The Test Results Indicate Drug-Induced Artifact, Not Primary Aldosteronism
The next step is to discontinue olmesartan for at least 4 weeks, correct any hypokalemia, and repeat the aldosterone-to-renin ratio (ARR) under standardized conditions; the current elevated renin activity (17.04 ng/mL/h) and low ARR (0.5) are caused by the angiotensin receptor blocker (ARB) and exclude primary aldosteronism. 1
Why These Results Are Artifactual
ARB Effect on Renin-Aldosterone Axis
Olmesartan (an ARB) stimulates renin secretion and suppresses aldosterone production, creating a falsely low ARR that can mask primary aldosteronism or, as in this case, produce results inconsistent with autonomous aldosterone secretion. 1, 2
The plasma renin activity of 17.04 ng/mL/h is markedly elevated (normal suppressed renin in primary aldosteronism is <1 ng/mL/h), indicating that the ARB is actively stimulating the renin-angiotensin system. 1
ACE inhibitors and ARBs may stimulate renin and suppress aldosterone, making interpretation of screening tests unreliable. 1
The ARR of 0.5 Rules Out Primary Aldosteronism
A positive screen for primary aldosteronism requires an ARR ≥30 (when aldosterone is in ng/dL and renin activity in ng/mL/h) plus plasma aldosterone ≥10 ng/dL. 1, 3, 1
This patient's ARR of 0.5 is 60-fold lower than the diagnostic threshold, effectively excluding primary aldosteronism even accounting for medication effects. 1, 4
Patients with primary aldosteronism typically have suppressed renin activity (<1 ng/mL/h), not elevated renin. 1
Standardized Retesting Protocol
Medication Withdrawal (4 Weeks Minimum)
Discontinue olmesartan at least 4 weeks before retesting to allow renin and aldosterone levels to return to baseline. 1, 3, 5, 4
Amlodipine may be continued during the washout period, as calcium channel blockers have minimal effect on the renin-aldosterone axis. 1, 2, 6
Alternative agents that do not interfere with testing include: alpha-1 blockers (doxazosin, prazosin, terazosin), long-acting non-dihydropyridine calcium channel blockers (verapamil, diltiazem), and hydralazine. 1, 5, 7
Pre-Test Standardization Requirements
Correct hypokalemia to within the normal laboratory range before testing, as low potassium suppresses aldosterone secretion and causes false-negative results. 1, 3, 5, 4
Ensure unrestricted dietary sodium intake (>200 mmol/day) for at least 3 days before sampling. 1, 5, 4
Collect blood samples in the morning after the patient has been seated for ≥15 minutes. 5, 4, 7
Clinical Context: Low-Renin Hypertension vs. Primary Aldosteronism
If Repeat ARR Remains Negative
An elevated renin activity off ARB therapy would indicate "renal phenotype" hypertension, best treated with ARBs or ACE inhibitors. 8
A low renin activity (<1 ng/mL/h) with low aldosterone would indicate volume-mediated ("V-type" or Liddle phenotype) hypertension, best treated with thiazide diuretics, amiloride, or calcium channel blockers—not ARBs. 7, 8, 9
If Repeat ARR Is Positive (ARR ≥30 and Aldosterone ≥10 ng/dL)
Proceed to confirmatory testing with saline suppression, oral salt loading, or captopril suppression test. 1, 3, 5, 4
If aldosterone is >20 ng/dL by immunoassay (or >15 ng/dL by LC-MS/MS) and renin is <0.2 ng/mL/h in the setting of resistant hypertension, no confirmatory test is required; proceed directly to adrenal CT and adrenal venous sampling. 4, 7
Common Pitfalls to Avoid
Do not interpret ARR while the patient is taking an ARB or ACE inhibitor; these agents can suppress aldosterone by 30% and elevate renin severalfold, yielding false-negative screens in up to 23.5% of cases. 2, 6
Do not rely on a single ARR measurement; intra-individual variability is high (coefficient of variation 41–42%), and 38% of patients with confirmed primary aldosteronism have at least one ARR below the diagnostic threshold. 10
Do not screen for primary aldosteronism in an 84-year-old with controlled blood pressure unless resistant hypertension, spontaneous hypokalemia, or an adrenal incidentaloma is present. 1, 3, 1
Age-Specific Considerations
Elderly patients (≥65 years) have decreased clearance of amlodipine, with a 40–60% increase in AUC; however, the current 5 mg dose is appropriate and well tolerated in this age group. 11, 12
Olmesartan 40 mg combined with amlodipine is safe and effective in patients ≥65 years, with no clinically relevant increase in adverse events compared to younger patients. 12
Blood pressure is currently controlled on the present regimen; there is no indication to intensify therapy or pursue secondary hypertension workup unless resistant hypertension develops after medication adjustment. 1